Not_yet_recruitingNCT07581288

Quantitative Hormonal Biomarkers of Uterine Cancer Progression in Patients With Abnormal Uterine Bleeding

Sponsor: University of British Columbia

Trial Details

Condition	Uterine Bleeding, Uterine Cancer, Uterine Neoplasms, Endometrial Cancer, Endometrial Hyperplasia, Endometrial Intraepithelial Neoplasia, Menstrual Cycle, Reproductive Endocrinology
Status	Not_yet_recruiting
Participants	50
Est. Completion	1 Sept 2026
Last Updated	12 May 2026

Primary Outcome

Urinary Hormone Levels (Mira Monitor); Menstrual Bleeding Severity; Acceptability and Feasibility of Mira Monitor

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * 35 years and older * Have experienced AUB Exclusion Criteria: * Currently pregnant or become pregnant during their participation * Previous surgeries impairing the menstrual cycle (e.g. hysterectomy, bilateral oophorectomy) * Currently or in the previous 3 months on medications that are known to impair or stimulate ovulation (e.g. oral contraceptives, ovulation stimulants, hormone replacement, etc.)

Trial Sites

Countries

Canada

View Registry Entry

Related Analysis

Novel Biomarker Study Opens: Urinary Hormones to Track Uterine Cancer Risk in Abnormal Bleeding — What Gynaecologists Need to Know

New Canadian study investigates urinary hormone biomarkers for detecting uterine cancer risk in women with abnormal bleeding. The research employs home-based monitoring technology to identify early malignant transformation patterns.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service